Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism
1Department of Internal Medicine, College of Medicine Ulsan University, Asan Medical Center, Seoul, Korea. steadyhan@amc.seoul.kr.
Abstract:
HMG-CoA reductase inhibitors, i.e. statins, are effective in reducing cardiovascular disease events but also in cardiac-related and overall mortality. Statins are in general well-tolerated, but currently the concerns are raised if statins may increase the risk of new-onset diabetes mellitus (NOD). In this review, the possible effects of statins on organs/tissues being involved in glucose metabolism, i.e. liver, pancreas, adipose tissue, and muscles, had been discussed. The net outcome seems to be inconsistent and often contradictory, which may be largely affected by in vitro experimental settings or/and in vivo animal conditions. The majority of studies point out statin-induced changes of regulations of isoprenoid metabolites and cell-associated cholesterol contents as predisposing factors related to the statin-induced NOD. On the other hand, it should be considered that dysfunctions of isoprenoid pathway and mitochondrial ATP production and the cholesterol homeostasis are already developed under (pre)diabetic and hypercholesterolemic conditions. In order to connect the basic findings with the clinical manifestation more clearly, further research efforts are needed.
Insights
Statins effectively reduce cardiovascular events but may increase new-onset diabetes mellitus (NOD) risk. Research explores statin effects on glucose metabolism organs, with findings often contradictory, possibly due to experimental conditions.
Area of Science:
- Biochemistry
- Endocrinology
- Pharmacology
Background:
- Statins (HMG-CoA reductase inhibitors) are widely used to reduce cardiovascular disease events and mortality.
- Concerns exist regarding a potential link between statin use and an increased risk of new-onset diabetes mellitus (NOD).
Purpose of the Study:
- To review the effects of statins on key organs involved in glucose metabolism: liver, pancreas, adipose tissue, and muscles.
- To analyze the conflicting evidence regarding statin-induced NOD and identify potential underlying mechanisms.
Main Methods:
- Literature review of in vitro and in vivo studies examining statin effects on glucose metabolism.
- Analysis of proposed mechanisms, including alterations in isoprenoid metabolites and cell cholesterol content.
Main Results:
- Statin effects on glucose metabolism appear inconsistent and contradictory, influenced by experimental settings.
- Statin-induced changes in isoprenoid regulation and cholesterol content are implicated in NOD risk.
- Pre-existing dysfunctions in isoprenoid pathways, ATP production, and cholesterol homeostasis in diabetic/hypercholesterolemic conditions may interact with statin effects.
Conclusions:
- The relationship between statins and NOD is complex and not fully elucidated.
- Further research is required to reconcile basic science findings with clinical observations and clarify the clinical implications of statin-induced NOD.
Related Concept Videos
00:46Feedback Inhibition
00:52What is Metabolism?
01:02Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:27Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:30Enzyme Inhibition
01:26Glucose Absorption Into the Small Intestine